Aptamer proteomics for biomarker discovery in heart failure with reduced ejection fraction (original) (raw)

Additional Information:

The PARADIGM-HF and ATMOSPHERE trials, and this proteomic study, were funded by Novartis.

Authors:

Zhang, L., Cunningham, J. W., Claggett, B. L., Jacob, J., Mendelson, M. M., Serrano-Fernandez, P., Kaiser, S., Yates, D. P., Healey, M., Chen, C.-W., Turner, G. M., Patel-Murray, N., Zhao, F., Beste, M. T., Laramie, J. M., Abraham, W. T., Jhund, P. S., Kober, L., Packer, M., Rouleau, J., Zile, M. R., Prescott, M. F., Lefkowitz, M., McMurray, J. J.V., Solomon, S. D., and Chutkow, W.

Publisher:

American Heart Association

Copyright Holders:

Copyright © 2022 American Heart Association, Inc.

First Published:

First published in Circulation 146(18): 1411-1414

Publisher Policy:

Reproduced in accordance with the publisher copyright policy